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Objectives: The aims of this study were to evaluate risk factors, clinical presentation, outcome and antimicrobial 
susceptibility in patients with Escherichia coli bacteremia occurring over seven years in a single cancer hospital. 
Methods: Sixty five episodes of bacteremia from E. coli appearing over seven years from 12,301 admissions in a single 
cancer institution were retrospectively analyzed. 
Results: The proportion of bacteremia caused by E. coli among Gram-negative bacteremia was 20.8% (the second 
most common organism after Pseudomonas aeruginosa), and infection-associated mortality was 17%.The incidence 
in 1989-1995 varied from 14.3 to 24.7%. The most common risk factors were: solid tumors as the underlying disease 
(70.7%); central venous catheter insertion (32.3%); prior surgery (46.2%), and prior chemotherapy within 48 h 
(44.4%). Neutropenia and urinary catheters did not place patients at high risk in any of the subgroups. When we 
compared the two subgroups of 61 cases of bacteremia - monomicrobial and polymicrobial (when E. coli was isolated 
from blood culture with another microorganism) - we found that acute leukemia and breakthrough (recurrence 
while receiving antibiotics) bacteremia were more frequently associated with polymicrobial E. coli bacteremia. There 
was also a difference in infection-associated mortality: monomicrobial bacteremia due to E. coli only had a signifi- 
cantly lower mortality in comparison with polymicrobial E. coZi bacteremia (8.9 vs 35.0%, respectively; P~0.03). 
Conclusion: The susceptibility of 115 E. coli strains isolated from 65 episodes of bacteremia was stable. Only two 
episodes caused by quinolone-resistant strains occurred, both in 1995, after six years of using ofloxacin for 
prophylaxis in neutropenic patients in our hospital. We found that 85.2-91.3% of all strains were susceptible to 
aminoglycosides, 97.8% to quinolones, and 90-100% to third generation cephalosporins and imipenems.The patients 
most commonly infected had solid tumors and the mortality was only 17%. 
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Enterobacteriaceae are some of the most common 
sources of nosocomial bloodstream infections and were 
the second most common group of organisms (following 
staphylococci) isolated from blood cultures in large 
epidemiologic studies in cancer patients.1,2 
Escherichiu coli isolated from blood cultures is 
generally susceptible to quinolones and third-generation 
cephalosporins; however, quinolone-resistant E. coli was 
reported in cancer centers using quinolones for infection 
prevention during neutropenia.3,4 Quinolone resistance 
in E. coli is still uncommon and appears in l-2% of all 
isolates from blood cultures in cancer centers using 
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quinolones either for prophylaxis or empiric therapy.5%6 
Resistance to third-generation cephalosporins and 
aminoglycosides by E. coli is steadily increasing and 
appears sometimes during initial (empiric) therapy.7 
Resistance to imipenem is exceptional. Mortality from 
E. coZi bacteremia in cancer patients is reported to be 
15-25%, and E. coli can cause septic shock with a fatal 
outcome. The mortality from E. coZi bacteremia is higher 
than that from Acinetobucter spp., Stenotrophomonas 
multophiliu, or staphylococcal bacteremias.2T8 
The aim of this investigation was to study incidence, 
epidemiology, risk factors, outcome and resistance to 
antimicrobials in cancer patients with bacteremia 
from E. coli within the last seven years in a single cancer 
hospital where quinolones have been used for pro- 
phylaxis since 1990. 
PATIENTS AND METHODS 
Patients 
We have observed 506 cases of gram-negative rod 
bacteremias among 869 bacteremic episodes from 
January 1,1989 until December 31, 1995, and 65 were 
due to E. coli. One hundred and fifteen strains of E. coli 
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were identified from 61 episodes. From patients charts we 
recorded: age, sex, underlying disease, central venous 
catheter, neutropenia 4OO/mL, colonization with E. coli 
of another body site, prior surgery, endoscopy (within 
seven days), prior chemotherapy, polymicrobial or mono- 
microbial cultures, prior prophylaxis with quinolones, 
prior therapy with third-generation cephalosporins and 
aminoglycosides, and susceptibility of isolated strains. 
Clinical symptoms and outcome were also recorded 
Methods 
Microbial identification was performed by Minitek 
(Becton Dickinson) systems until 1993 and with Vitek Jr 
identification system (Vitek, Bio Merieux) since 1993. 
Routine blood culturing has been used since 1990. MIC 
for isolated organisms were determined according to the 
NCCLS standards after 1992, and before 1992 with a 
disk diffusion method. The antimicrobials tested for 
susceptibility, resistance and breakpoints are listed in 
Table 1. 
Statistical analysis 
Univariate analysis with X2 test and Fisher’s exact test 
were used to compare continuing variables and PxO.05 
was considered as significant. Variables in subgroups of 
episodes caused by monomicrobial versus polymicrobial 
bacteremia were compared. 
Antibiotic policy 
In our cancer center, the antibiotic policy since 1990 has 
allowed the use of an oral quinolone (ofloxacin 200 mg 
bid) for prevention of infection, in afebrile neutropenic 
(~500 PMN/mL) patients with hematologic malignancy. 
Ceftriaxone plus netilmicin or cefotaxime plus 
pefloxacin are used in febrile neutropenia for empiric 
therapy. In acute leukemia, amikacin plus ceftazidime 
are used as first-line therapy, and vancomycin is added 
in nonresponding fever, according to the Infectious 
Diseases Society of America (IDSA) guidelines. 
Imipenem has been used since 1991 in our center in 
nonresponding fever together with vancomycin and 
Table 1. Susceptibility of E, co/i to selected antimicrobial agents (1990-1995) 
Number of sensitiveltotal (%) 
7990 1991 1992 1993 1994 1995 Total 
AMP 132 014 (0) 2/l 0 (20.0) 4/23 (17.3) 5/19 (26.3) 12/20 (60.0) 6/28 (21.4) 29/l 15 (25.2) 
CEFAZ 18 o/4 (0) 6/10 (10.0) 15/23 (65.2) 12/19 (63.1) 18/20 (90.0) 20/28 (71.4) 71/115 (61.8) 
CTAZ ~'32 2/4 (50.0) 9/l 0 (90.0) 19/23 (82.7) 17/19 (89.5) 20/20 (100.0) 27/28 (96.4) 104/l 15 (90.4) 
CTRX <32 2/4 (50.0) 8/l 0 (80.0) 19/23 (82.7) 16/l 9 (84.2) 20/20 (100.0) 26/28 (92.9) 101/l 15 (87.8) 
CFUR <32 214 (50.0) 8/l 0 (80.0) 18/23 (78.3) 16/l 9 (84.2) 20/20 (100.0) 26/28 (98.9) 101/l 15 (87.8) 
CTAX ~32 2/4 (50.0) 8/l 0 (80.0) 19/23 (82.7) 16/l 9 (84.2) 20/20 (100.0) 26/28 (92.9) 102/l 15 (88.7) 
OFL <8 4/4 (100.0) IO/IO (100.0) 23/23 (100.0) 19/19 (100.0) 20/20 (100.0) 26/28 (92.9) 113/115 (98.3) 
GEN 18 2/4 (50.0) 7/l 0 (70.0) 18723 (78.3) 15/19 (78.9) 20/20 (100.0) 28/28 (100.0) 101/115 (87.8) 
NET <8 2/4 (50.0) 8/l 0 (80.0) 20/23 (86.9) 16/l 9 (84.2) 20/20 (100.0) 28/28 (100.0) 105/115 (91.3) 
TOB <8 2/4 (50.0) 6/l 0 (60.0) 19/23 (82.7) 15/l 9 (78.9) 20/20 (100.0) 27/28 (96.4) 100/l 15 (86.9) 
AMI <I6 4/4 (100.0) 8/l 0 (80.0) 12723 (52.1) 15/l 9 (78.9) 20/20 (100.0) 28/28 (100.0) 98/l 15 (85.2) 
TIC 132 l/4 (25.0) ND ND 19120 (91 .O) 20/28 (71.4) 40/52 (78.5) 
MER <8 ND ND 18$94.7) 20/20 (100.0) 28/28 (100.0) 66/67 (98.5) 
CIP ~8 23,::(100.0) 19/19 (100.0) 20/20 (100.0) 26/28 (92.9) 88/90 (97.8) 
COT 132 2::(50.0) 9/E?(90.0) 20/23 (86.9) 19/19 (100.0) 19/20 (91.0) 24/28 (85.7) 104/I 15 (90.4) 
Abbreviations: CMP - chloramphenicol, AMP - ampicillin, STM -streptomycin, GEN - gentamicin, TOB - tobramycin, NET - netilmicin, AMI - amikacin, 
CFUR - cefuroxime, CEFAZ - cefazoline, CTAZ - ceftazidime, AZL - azlocillin, TIC - ticarcillin, OFL - ofloxacin, 
COL - colymicine, COT - cotrimoxazole, MER - meropenem, CIP - ciprofloxacin, CTRX - ceftriaxone, CTAX - cefotaxime 
Table 2. Etiology of bacteremia and fungemia at the National Cancer institute in 1989-1995 
1989 1990 1991 1992 1993 1994 7995 Total 
Number of admissions (A) 
No. of bacteremic episodes (E) (%E/A) 
Number of Blood cultures obtained 
Deaths due to bacteremia 
Deaths per episode (%) 
Prophylaxis with ofloxacin 
Prophylaxis with fluconazole 
Prophylaxis with V-penicillin 
Therapeutic regimens 
most frequently used 
1205 
26 (2.1%) 
435 
9 
33,3% 
- 
- 
- 
OXAtGEN 
CTAXtGEN 
CTAZtAMl 
1490 1545 
36 (2.4%) 78 (5%) 
895 2001 
10 9 
27.7% 11,5% 
- -I- 
- - 
CTAZtAMI CTRXtNET 
CTAXtGEN CTAZtAMl 
1615 1970 2161 2315 12301 
121 (7,1%) 158 (8%) 239 (11,1%)211 (9.1%) 869 
2687 2516 2505 3280 14479 
10 13 12 14 77 
3.6% 8,2% 3,0% 2.4% 8.9% 
+ + + + 
+ + + + 
- - + + 
CTAZ+AMI CTRXtNET CTAZtAMl CTAZtAMl 
CTRXtNET CTAZtAMI CTRXtNET CTRXtNET 
Abbreviations: OXA - oxacillin, GEN - gentamicin, AMI - amikacin, CTAZ - ceftazidime, CTAX - cefotaxime, CTRX - ceftriaxone, NET - netilmicin 
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amikacin or colimycin, only after failure of first line 
therapy, or for documented systemic Pseudomonas 
aeruginosa infections, with amikacin or colimycin. 
Definitions 
(a) 
(b) 
(cl 
(4 
(4 
(0 
63) 
(h) 
Bacteremia was defined by the isolation of E. coli 
from two or more blood cultures or from a single 
blood culture if there was a clinically apparent and/ 
or culture-positive other source of infection. 
Source of bacteremia was defined as a culture- 
positive site or a clinically apparent site of infection. 
If blood was the only culture-positive specimen and 
there was no apparent source of infection, the 
source of bacteremia was considered unknown. 
Polymicrobial bacteremia was defined by the 
isolation of organisms in addition to E. cob either 
from the same blood culture or from multiple 
cultures performed during a single bacteremic 
episode. 
Patients were considered neutropenic if their 
absolute neutrophil count was <500/mm3 at the 
onset of bacteremia. 
Septic shock was defined by sepsis associated with 
evidence of organ hypoperfusion and a systolic 
blood pressure that was ~90 mmHg or >30 mmHg 
less than the baseline value, or intravenous fluids or 
vasopressors were needed to maintain blood 
pressure. 
Mortality from bacteremia (attributable mortality) 
was defined as death with clinical signs of active 
infection and a positive blood culture result. 
Death, appearing up to five days after a bacteremic 
episode, but not clearly associated with sepsis and/or 
shock, was considered as death with bacteremia 
(crude mortality). 
Relapse was defined as a positive blood culture 
appearing within 10 days after initial improvement 
or cure. 
RESULTS 
Incidence and etiology 
From 2000 bacterial isolates from blood cultures in 
cancer patients between January 1,1989 and December 
31, 1995 hospitalized in the 360 bed National Cancer 
Institute (Table 2) reference cancer institute for the 
Slovak Republic (5.5 million population), 506 (26.8%) 
were Gram-negative bacteria; 115 (20.8%) of Gram- 
negative bacteria were due to E. coli. E. coli was the 
second most common isolate from blood cultures in our 
cancer patients (after Pseudomonas aeruginosa). The 
proportion of E. coli among Gram-negative bacteremia 
cases in 1989-1995 was 20.8%, and varied from 12.4% 
(1994) to 36.3% in 1990 (Table 2, Table 3). 
Risk factors and outcome 
The commonest risk factors in E. coli bacteremia cases 
in our cancer patient population were: solid tumors as 
the underlying disease (70.7%), previous chemotherapy 
(44.6%) and prior surgery within 10 days (46.2%), and 
vascular catheter insertion (32.3%); 69.2% were 
monomicrobial. The overall cure rate was 76.9%, and 
the attributable mortality was 17%. 
Third-generation cephalosporins alone or in combin- 
ation with an aminoglycoside were the most common 
treatment regimens. Six patients with monomicrobial 
bacteremia were not cured using antibiotic therapy, but 
were cured by catheter removal (Table 4). 
Comparison of monomicrobial to polymicrobial 
episodes 
When 45 monomicrobial episodes were compared 
with 20 polymicrobial episodes (where E. coli was 
found in blood cultures together with Streptococcus 
viridans, Enterococcus spp., Candida spp., coagulase- 
negative staphylococci, Klebsiella spp. or Pseudomonas 
Table 3. Trends in etiology of Gram-negative bacteremias within 1989-1995 
Number of isolates per year (%) 
G-bacteria 1989 1990 1991 1992 1993 1994 1995 Total 
Pseudomonas aeruginosa 5 (71.4) 0 (0) 5 (9.2) 20 (21.8) 22 (28.5) 46 (30.7) 41 (35.6) 139 (27.5) 
E. coli 1 (14.3) 4 (36.3) 10 (18.5) 23 (25.0) 19 (24.7) 20 (12.4) 28 (24.3) 115 (20.8) 
Acinetobacter calcoaceticus 1 (14.3) 0 (0) 11 (20.3) 12 (13.0) 10 (13.0) 17 (11.3) 11 (9.5) 62 (12.2) 
Klebsiella spp. 0 (0) 6 (54.5) 20 (37.0) 6 (6.5) 7 (9.1) 12 (8.0) 10 (8.7) 
Enterobacter spp. 
61 (12.1) 
0 (0) 0 (0) 2 (3.7) 10 (10.9) 5 (6.5) 24 (16.0) 
Stenotrophomonas maltophilia 
10 (8.7) 51 (10.1) 
0 03 0 (0) 0 (0) 10 (10.9) 6 (7.8) 7 (4.7) 8 (7.0) 31 (6.1) 
Proteus spp. 0 (0) 0 (0) 3 (5.6) 3 (3.3) 8 (10.4) 9 (6.0) 2 
Pseudomonas cepacia 
(1.7) 25 (4.9) 
0 (0) 0 (0) 0 03 5 (5.4) 0 (0) 10 (6.7) 0 (0) 
Flavobacterium spp. 
15 (2.9) 
0 (0) 0 (0) 4 (7.4) 0 (0) 0 (0) 0 (0) 
Alcaligenes fecalis 
1 (0.9) 5 (0.9) 
0 (0) 1 (9.2) 0 (0) 0 (0) 0 (0) 3 (2.0) 
Citrobacter 
0 (0) 4 (0.8) 
spp. 0 (0) 0 (0) 1 (1.9) 0 (0) 0 (0) 1 (0.7) 2 (1.7) 
Serratia spp. 
4 (0.8) 
0 (0) 0 (0) 0 (0) 1 (1.1) 0 (0) 1 (0.7) 2 (1.7) 
Hafnia alvei 
4 (0.8) 
0 (0) 0 (0) 0 (0) 1 (1.1) 0 (0) 0 (0) 0 (0) 
Salmonella spp. 
1 (0.2) 
0 (0) 0 (0) 0 (0) 1 (1.1) 0 (0) 0 (0) 0 (0) 1 (0.2) 
Gram-negative bacteria (total) 7 (17.5) 11 (12.3) 54 (32.0) 92 (28.6) 77 (21.6) 150 (30.9) 115 (26.4) 506 (26.8) 
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aeruginosa), only acute leukemia and breakthrough 
bacteremia were more frequently associated with 
polymicrobial E. coli episodes. Septic shock (50 vs 8.9%, 
P<O.O05) and attributable mortality(35.0 vs 8.9%, 
PcO.03) were significantly higher among polymicrobial 
than monomicrobial E. coli episodes (Table 4). 
Susceptibility to antimicrobials 
Table 1 shows the susceptibility of 115 strains of E. coli 
to antibiotics causing 65 bacteremic episodes in 
1990-1995. The lowest resistance rates were observed 
for ciprofloxacin and ofloxacin (98.3%) meropenem 
(98.5%), colimstin (93.9%) and netilmicin (91.3%). 
Annual percentages of resistant strains did not show any 
significant changes in 1994-1995 in comparison with 
1990-1991. Only two quinolone-resistant E. coli were 
observed, both in 1995. Resistance to cefotaxime is 
decreasing. 
DISCUSSION 
The incidence of E. coli bacteremia was stable from 1990 
to 1995; however, after the introduction of quinolones, 
mortality from bacteremia decreased more than lo-fold, 
from 33.30 (1990) to 2.4% (1995).Attributable mortality 
from E. coli was higher (17%) but when monomicrobial 
bacteremia from E. coli infection alone was taken into 
account, associated mortality was only 8.9%, which is 
lower than that reported from other centers.1J,7 How- 
ever, when E. coli caused bacteremia together with 
other bacteria (20 of polymicrobial episodes were due 
to E. coli plus enterococci, staphylococci, Klebsiella 
pneumoniue, yeasts, pseudomonads), the mortality from 
bacteremia was significantly higher (35.0%) and similar 
to other gram-negative bacilli.3J 
Resistance to quinolones in our institute was 
relatively low in comparison with other surveillance 
studies from cancer centers.Q Only two bacteremic 
episodes were due to ofloxacin and ciprofloxacin (MIC 
>8 mmol/L)-resistant Enterobacter cloacae. This is 
surprisingly low (despite the use of oral ofloxacin in 
prevention of infection in patients with hematologic 
malignancies since 1990) and may be because of limited 
use of quinolones in therapy. We did not observe any 
outbreaks of quinolone-resistant E. coli as reported 
from other cancer centers with a similar prophylactic 
strategy.3,4 Most E. coli bacteremic episodes appeared in 
Table 4. E. co/i bacteremia in cancer patients. Risk factors and outcome: monomicrobial versus polymicrobial 
bacteremias 
Total Monomicrobial Polymicrobial PC 
No. of pts. 65 45 20 
Risk factors 
Males 
Females 
Age r60 
Underlying disease 
-Acute leukemia 
-Other hematologic malignancies 
-Solid tumors 
Neutropenia ~500 (N) 
Previous chemotherapy 
Diabetes mellitus 
Previous surgery 
Previous endoscopy 
Central venous catheter 
Urinary tract catheter 
Source of bacteremia 
-Urinary tract 
-Gastrointestinal tract 
-Infected wound 
-Infected catheter 
Prior colonization 
No of positive cultures/patients/cultures ratio 
36(55.4) 
29 (44.6) 
25 (38.5) 
25 (55.5) 
20 (45.5) 
19 (42.2) 
12 (18.5) 
7 (10.8) 
46 (70.0) 
13 (20.0) 
29 (44.6) 
5 (7.7) 
30 (46.2) 
8 (12.3) 
21 (32.3) 
15 (23.1) 
4 (8.9) 
6 (13.4) 
35 (77.7) 
9 (20.0) 
17 (37.8) 
3 (6.7) 
22 (48.9) 
6 (13.4) 
17 (37.8) 
11 (24.4) 
8 (12.3) 
9 (13.9) 
7 (10.8) 
6 (9.2) 
8 (12.3) 
115165 
11 (55.0) 
9 (45.0) 
6 (30.0) 
8 (40.0) 
1 (5.0) 
11 (55.0) 
4 (20.0) 
12 (60.0) 
2 (10.0) 
8 (40.0) 
2 (10.0) 
4 (20.0) 
4 (20.0) 
2 (10.0) 
3 (15.0) 
4 (20.0) 
4 (20.0) 
1 (5.0) 
54154120 
=2.7 
Breakthrough bacteremia 
-0FL resistant 
-during OFL prophylaxis 
-during empiric therapy 
-with AMOICLAV 
-with NET+CTAX 
-with AMI+CTAZ 
20 (30.8) 
2 (3.1) 
4 (6.1) 
17 (24.7) 
4 (6.1) 
4 (6.1) 
6 (9.2) 
6 (13.4) 
6 (13.4) 
3 (6.7) 
2 (4.2) 
7 (15.6) 
6ll6ll45 
=I.36 
2 (4.2) 
1 (2.1) 
2 (4.2) 
1 (2.1) 
0 (0) 
0 (0) 
0 (0) 
18 (90.0) 
1 (5.0) 
2 (10.0) 
16 (80.0) 
4 (20.0) 
4 (20.0) 
6 (30.0) 
Outcome 
Cure 
Death due to underlying disease 
Death due to bacteremia 
50 (76.9) 38 (84.4) 12 (60.0) 0.05 
4 (6.1) 3 (6.7) 1 (5.0) NS 
11 (17.0) 4 (8.9) 7 (35.0) 0.03 
NS 
NS 
NS 
0.005 
NS 
N5 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
- 
0.001 
NS 
NS 
0.001 
- 
- 
- 
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non-neutropenic patients (80.0% of episodes were in 
non-neutropenic patients) in contrast to Streptococcus 
viridans, Enterococcus faecalis, and Pseudomonas 
aeruginosa, which caused bacteremia more frequently in 
neutropenic patients with acute leukemia.2,5-7 
Prior surgery as a common risk factor for E. coli for 
both cancer and non-cancer patients is reported world- 
wide2,5,6 and occurred in 46.2% bacteremic episodes 
caused by E. coli in our patient population. 
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